TCGA-66-2793-01A-01R-1201-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V1+0.420
- MYC_TARGETS_V2+0.360
- DNA_REPAIR+0.280
- MITOTIC_SPINDLE+0.220
- SPERMATOGENESIS+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.120
- WNT_BETA_CATENIN_SIGNALING+0.110
- MTORC1_SIGNALING+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.620
- INFLAMMATORY_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.580
- IL6_JAK_STAT3_SIGNALING-0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- COAGULATION-0.520
- COMPLEMENT-0.520
- KRAS_SIGNALING_UP-0.500
- ANGIOGENESIS-0.490
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-04013 | — | cohortMD1 | 0.967 |
| 2 | BS_9V633J1X | medulloblastoma | — | 0.961 |
| 3 | BS_JFB984RG | medulloblastoma | — | 0.961 |
| 4 | BS_BSV07M7Z | medulloblastoma | — | 0.956 |
| 5 | BS_TZVFR600 | medulloblastoma | — | 0.956 |
| 6 | BS_Y8D1F5WW | medulloblastoma | — | 0.955 |
| 7 | BS_K74PZET7 | medulloblastoma | — | 0.954 |
| 8 | BS_GE2RVZE6 | medulloblastoma | — | 0.953 |
| 9 | BS_G00FHF3Q | medulloblastoma | — | 0.953 |
| 10 | BS_GNV89A5P | medulloblastoma | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |